After Stopping a GLP-1: Weight-Regain Evidence
Weight regain after treatment withdrawal is common in randomized studies. The often-quoted “two-thirds” result is the mean share of prior semaglutide-associated weight loss regained by STEP 1 extension participants over the following year. It does not mean two-thirds of people regained weight. No trial has shown that a 12-week taper, a fixed carbohydrate ladder, or keto reliably prevents the rebound.
Do not stop, stretch doses, or create a taper without the prescriber. Treatment may have been addressing diabetes, obesity, cardiovascular risk, sleep apnea, or another indication, and the plan for other medicines can change when it ends. Tirzepatide is a dual GIP/GLP-1 medicine, so results from semaglutide should not automatically be assigned to it.
What STEP 1 showed after semaglutide withdrawal
Participants in STEP 1 received semaglutide 2.4 mg or placebo with lifestyle intervention for 68 weeks, then stopped the trial product and structured lifestyle intervention. In the extension cohort, the semaglutide group regained an average 11.6 percentage points of body weight from week 68 to week 120. That equaled about two-thirds of the weight they had previously lost. Their net mean change from baseline at week 120 was still -5.6%.1
The result is an average from a trial extension with selected sites and participants. It should not be restated as “two-thirds of patients regain,” and it cannot predict an individual's course.
What SURMOUNT-4 showed after tirzepatide withdrawal
SURMOUNT-4 used a randomized-withdrawal design. After a 36-week open-label tirzepatide lead-in, 670 participants were randomized either to continue their maximum tolerated dose or switch to placebo for 52 weeks. From randomization to week 88, the continued-treatment group lost another 5.5% on average, while the placebo-switch group gained 14.0%.2
The withdrawal group still had a net reduction from the original study baseline, but most regained a meaningful portion. This trial supports a treatment-continuation effect for tirzepatide under that protocol. It does not test a ketogenic off-ramp.
Why the plan should begin with the diagnosis
WHO's 2025 guideline treats obesity as a chronic, relapsing disease requiring long-term care. It conditionally recommends GLP-1 therapies as a long-term option for adults with obesity, excluding pregnancy from the recommendation, and pairs medicine with behavioral support and follow-up.3 “Long-term option” does not mean every patient stays on the same medicine forever. It means discontinuation deserves the same clinical planning as initiation.
Before a planned change, ask:
- Why is treatment stopping: adverse effects, pregnancy planning, access, response, preference, or a change in diagnosis?
- Which glucose, blood-pressure, or other medicines need review?
- How will appetite, weight, waist, glucose when relevant, nutrition, and symptoms be followed?
- What is the plan if weight or the treated condition worsens?
- Which eating and activity pattern is realistic without medication-supported appetite reduction?
What exercise evidence can support
One randomized study began with an eight-week low-calorie diet, then compared one year of supervised exercise, liraglutide 3.0 mg, both, or placebo. A post-treatment analysis found that one year after all active treatment ended, the earlier exercise-plus-liraglutide group maintained lower weight and body-fat percentage than the earlier liraglutide-only group.4
That is encouraging evidence for building an exercise routine during treatment. It involved liraglutide, a specific program, and a selected population. It cannot establish the same effect for semaglutide, tirzepatide, unsupervised exercise, or keto.
Resistance work can support strength and function, while aerobic activity contributes cardiovascular and fitness benefits. The program should match health, mobility, and experience. See the GLP-1 lean-mass guide for measurement limits and individualized protein context.
Does keto prevent regain?
No randomized withdrawal trial has established keto as a way to prevent regain after semaglutide or tirzepatide. A lower-carbohydrate pattern may help some people organize food or manage glucose, but it can also be difficult to sustain and may interact with diabetes medicines. Carb restriction itself does not guarantee an energy intake, protein adequacy, muscle preservation, or weight stability.
If keto is being considered, define the actual food pattern and review GLP-1 medicines versus keto. Avoid a fixed schedule such as “add 5-10 grams every week”; evidence does not establish that as a medical off-ramp.
The keto calculator is an input-only macro arithmetic worksheet. It calculates results from values you enter; it does not choose a personalized protein or macro target.
Build a follow-up plan that can change
A useful plan has actions and review points:
| Area | Before the change | During follow-up |
|---|---|---|
| Medication | Confirm stop or transition instructions | Report adverse effects or disease worsening |
| Food | Choose a nutritionally adequate, feasible pattern | Review hunger, intake, tolerance, and access |
| Activity | Establish a scalable routine | Track attendance, strength, and function |
| Measurements | Record agreed baseline measures | Look at trends, not one day's number |
| Support | Schedule clinical and nutrition follow-up | Escalate early rather than waiting for large regain |
Return of hunger is a pharmacologic and biological change, not proof of weak character. If the plan is failing, revising care is more useful than adding untested restrictions.
Frequently Asked Questions
Did two-thirds of people regain weight after stopping semaglutide?
Should a GLP-1 medicine be tapered over 12 weeks?
Does keto stop weight regain after a GLP-1?
What did SURMOUNT-4 test?
Can exercise help after treatment stops?
Works cited
Article history
- Corrected withdrawal statistics and replaced an untested taper with trial-grounded long-term follow-up guidance
- First published
Your learning guide
Loading reading status…